Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Featured Technologies

VAL401 – for the treatment of adenocarcinoma

Opportunity ContactMark Treharne, Head of Corporate DevelopmentLondon, United Kingdom ValiRx Website Pharmalicensing.com VAL401 is the reformulation of the anti-psychotic drug Risperidone in a lipid-based capsule which enables anti-cancer biology that is not

November 2, 2020
Read more
Featured Technologies

BC201 – Treatment for Coronavirus Patients

BC201 is a combination of the peptide ingredient of VAL201 (a decapeptide currently in clinical testing for Oncology) with complementary active components to dampen this excessive immune response and consequently improve severe

November 2, 2020
Read more
Newer postsOlder posts

2020 Cognis Group. All Rights Reserved.